Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)—study protocol for a phase 2, randomized, placebo controlled trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)—study protocol for a phase 2, randomized, placebo controlled trial
Authors
Keywords
-
Journal
Trials
Volume 23, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-05-23
DOI
10.1186/s13063-022-06356-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The JAK1 Selective Inhibitor ABT 317 Blocks Signaling Through Interferon-γ and Common γ Chain Cytokine Receptors to Reverse Autoimmune Diabetes in NOD Mice
- (2020) Tingting Ge et al. Frontiers in Immunology
- The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
- (2020) William Damsky et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Baricitinib for systemic lupus erythematosus – Authors' reply
- (2019) Daniel J Wallace et al. LANCET
- Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis
- (2019) Charalampia Papadopoulou et al. BRAIN
- Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
- (2019) Anniina T. Virtanen et al. BIODRUGS
- JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
- (2018) Gina A. Montealegre Sanchez et al. JOURNAL OF CLINICAL INVESTIGATION
- Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
- (2018) Emma Guttman-Yassky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Daniel J Wallace et al. LANCET
- Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables
- (2018) John M. Wentworth et al. DIABETOLOGIA
- Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
- (2018) Josef S. Smolen et al. JOURNAL OF RHEUMATOLOGY
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
- (2017) Roy Fleischmann et al. Arthritis & Rheumatology
- Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response
- (2017) Matthew Clark et al. Frontiers in Immunology
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
- (2016) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- A model-based approach to sample size estimation in recent onset type 1 diabetes
- (2016) Brian N. Bundy et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases
- (2015) Yun R Li et al. NATURE MEDICINE
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- (2015) Ali Jabbari et al. EBioMedicine
- Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
- (2014) Edward C Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- Proinflammatory cytokines contribute to development and function of regulatory T cells in type 1 diabetes
- (2012) Helen E. Thomas et al. Annals of the New York Academy of Sciences
- Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
- (2012) C. J. Greenbaum et al. DIABETES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now